Dr. med. Christa Flechtenmacher

Quality manager, Institute of Pathology, University of Heidelberg

Senior pathologist, Institute of Pathology, University of Heidelberg Head of teaching program for dental school students

Board Certification Pathology

Institute of Pathology, University of Heidelberg

Sigel-Hospital, Langenbrücken, Internal medicine and gynecologic oncology

MD-Thesis (Functional characterization of the role of PTH in the pathogenesis of myocardial fibrosis and microarteriopathy in experimental uremia) Institute of Pathology, University of Heidelberg

Institute of Pathology, Darmstadt

University of Heidelberg/ Germany

University of Zürich/ Switzerland

University of Minnesota and Yale University/ USA

University of Heidelberg/ Germany

Study of Medicine, scholarship Evangelisches Studienwerk e.V. Villigst (German protestant church`s scholarship programme for gifted students)

University of Bochum/ Germany

Diagnostics and research: tumours of the head and neck, molecular and morphological carcinogenesis (especially oral squamous cell carcinoma); liver and heart transplantation, tumours of the breast and female genital organs. Teaching: new methods (e.g. implementation of an interviewing technique program with simulated relatives of passed away patients). Quality management in medical institutions.

Freier K, Pungs S, Sticht C, Flechtenmacher C, Lichter P, Joos S, Hofele CHigh survivin expression is associated with favorable outcome in advanced primary oralsquamous cell carcinoma after radiation therapy. Int J Cancer. 2007 Feb 15;120(4):942-6.

Freier K, Schwaenen C, Sticht C, Flechtenmacher C, Muhling J, Hofele C, Radlwimmer B, Lichter P, Joos S.Recurrent FGFR1 amplification and high FGFR1protein expression in oral squamous cellcarcinoma (OSCC).Oral Oncol. 2007 Jan; 43(1):60-6. Epub 2006 Jun 27.

Freier K, Schwaenen C, Sticht C, Flechtenmacher C, Muhling J, Hofele C, Radlwimmer B, Lichter P, Joos S. Recurrent FGFR1 amplification and high FGFR1protein expression in oral squamous cellcarcinoma (OSCC). Oral Oncol. 2007 Jan;43(1):60-6. Epub 2006 Jun 27.

Berberat PO, Friess H, Schmied B, Kremer M, Gragert S, Flechtenmacher C, Schemmer P, Schmidt J, Kraus T, Uhl W, Meuer S, Buchler MW, Giese T.Differentially expressed genes in postperfusionbiopsies predict early graft dysfunction after liver transplantation. Transplantation. 2006 Sep 15;82(5):699-704

Schemmer P, Liang R, Kincius M, Flechtenmacher C, Bunzendahl H, Gutt CN, Mehrabi A, Gebhard MM, Buchler MW, Kraus TW Taurine improves graft survival after experimental liver transplantation. Liver Transpl. 2005 Aug;11(8):950-9. 

Herpel E, Singer S, Flechtenmacher C, Pritsch M, Sack FU, Hagl S, Katus HA, Haass M, Otto HF, Schnabel PA. Extracellular matrix proteins and matrix metalloproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies.
Virchows Arch. 2005 Apr;446(4):369-78. Epub 2005 Apr 2. 

Bosch FX, Ritter D, Enders C, Flechtenmacher C, Abel U, Dietz A, Hergenhahn M, Weidauer H. Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but thesehave limited prognostic value. Int J Cancer 2004 Sep 10;111(4):530-8. 

Szabo G, Soos P, Mandera S, Heger U, Flechtenmacher C, Bahrle S, Seres L, Cziraki A, Gries A, Zsengeller Z, Vahl CF, Hagl S, Szabo C. INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac andpulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock. 2004 May;21(5):426-32.

Engler S, Flechtenmacher C, Wiedemann KH, Gugler R, Stremmel W, Kallinowski B Interferon alfa2a induction therapy in combination with ribavirin and amantadine for thetreatment of naive patients with chronic HCV infection. J Viral Hepat. 2004 Jan;11(1):60-8.

Engler S, Elsing C, Flechtenmacher C, Theilmann L, Stremmel W, Stiehl A Progressive sclerosing cholangitis after septic shock: a new variant of vanishing bile ductdisorders. Gut. 2003 May;52(5):688-93. 

Freier K, Joos S, Flechtenmacher C, Devens F, Benner A, Bosch FX, Lichter P, Hofele C. Tissue microarray analysis reveals site-specific prevalence of oncogene amplifications inhead and neck squamous cell carcinoma. Cancer Res. 2003 Mar 15;63(6):1179-82.

Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX.Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers withunaltered p53 status and perturbed pRb cell cycle control. Oncogene. 2002 Feb 28;21(10):1510-7.